← All trials
NCT04320316
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2020
- Primary completion
- Apr 15, 2021
- Completion date
- Oct 15, 2021
- First posted
- Mar 25, 2020
- Last posted
- Mar 26, 2020
- Enrollment
- 1
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Alabama, BirminghamLead sponsor
- University of Alabama, BirminghamOverall official - principal investigator
- University of Alabama, BirminghamReponsible party - principal investigator
- Ultragenyx Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.